134 related articles for article (PubMed ID: 25765719)
1. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications.
Neishaboori N; Wadhwa R; Nogueras-González GM; Elimova E; Shiozaki H; Sudo K; Charalampakis N; Hiremath A; Lee JH; Bhutani MS; Weston B; Blum MA; Rogers JE; Garris JL; Rice DC; Komaki R; Swisher SG; Skinner HD; Hofstetter WL; Ajani JA
Oncology; 2015; 89(2):65-9. PubMed ID: 25765719
[TBL] [Abstract][Full Text] [Related]
2. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
3. [Residual esophageal cancer after neoadjuvant chemoradiotherapy: frequently the mucosa and submucosa are involved].
Brink F; Jähne J
Chirurg; 2014 Mar; 85(3):257. PubMed ID: 24519613
[No Abstract] [Full Text] [Related]
4. Residual Esophageal Cancer After Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa.
van Rossum PSN; van Hillegersberg R; Meijer GJ; Ruurda JP
Ann Surg; 2015 Aug; 262(2):e83-4. PubMed ID: 24743619
[No Abstract] [Full Text] [Related]
5. Reply to Letter: "Residual Esophageal Cancer After Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa".
Shapiro J; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2015 Aug; 262(2):e84-5. PubMed ID: 24743617
[No Abstract] [Full Text] [Related]
6. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma.
Estrella JS; Hofstetter WL; Correa AM; Swisher SG; Ajani JA; Lee JH; Bhutani MS; Abraham SC; Rashid A; Maru DM
Am J Surg Pathol; 2011 Jul; 35(7):1045-53. PubMed ID: 21602659
[TBL] [Abstract][Full Text] [Related]
7. Importance of residual primary cancer after induction therapy for esophageal adenocarcinoma.
Raja S; Rice TW; Ehrlinger J; Goldblum JR; Rybicki LA; Murthy SC; Adelstein D; Videtic G; McNamara MP; Blackstone EH
J Thorac Cardiovasc Surg; 2016 Sep; 152(3):756-761.e5. PubMed ID: 27530636
[TBL] [Abstract][Full Text] [Related]
8. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma.
Shiozaki H; Slack R; Sudo K; Elimova E; Wadhwa R; Chen HC; Skinner HD; Komaki R; Lee JH; Weston B; Bhutani MS; Blum MA; Rogers JE; Maru DM; Hofstetter WL; Ajani JA
Oncology; 2015; 88(6):332-6. PubMed ID: 25765098
[TBL] [Abstract][Full Text] [Related]
9. Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection.
Probst A; Aust D; Märkl B; Anthuber M; Messmann H
Endoscopy; 2015 Feb; 47(2):113-21. PubMed ID: 25479563
[TBL] [Abstract][Full Text] [Related]
10. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
11. Stage III esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery.
Schlottmann F; Strassle PD; Gaber C; Patti MG
Updates Surg; 2018 Dec; 70(4):423-426. PubMed ID: 29926306
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
13. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients.
Mizrak Kaya D; Dong X; Nogueras-González GM; Xu Y; Estrella JS; Harada K; Lopez A; Amlashi FG; Hofstetter WL; Maru DM; Nguyen QN; Lee JH; Weston B; Bhutani MS; Erasmus JJ; Thomas I; Rogers JE; Song S; Ajani JA
Med Oncol; 2017 Aug; 34(8):135. PubMed ID: 28685276
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.
Schölvinck D; Künzli H; Meijer S; Seldenrijk K; van Berge Henegouwen M; Bergman J; Weusten B
Surg Endosc; 2016 Sep; 30(9):4102-13. PubMed ID: 27357927
[TBL] [Abstract][Full Text] [Related]
15. Depth of
Seder CW; Mahon B; Hennon M; Thomas M; Levea CM; Matkowskyj KA; Krishna M; Medairos R; Macke RA; Basu S; Blasberg JD
Anticancer Res; 2018 Apr; 38(4):2195-2200. PubMed ID: 29599339
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
17. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma.
Lewis JT; Wang KK; Abraham SC
Am J Surg Pathol; 2008 Apr; 32(4):566-71. PubMed ID: 18300796
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Steins A; Ebbing EA; Creemers A; van der Zalm AP; Jibodh RA; Waasdorp C; Meijer SL; van Delden OM; Krishnadath KK; Hulshof MCCM; Bennink RJ; Punt CJA; Medema JP; Bijlsma MF; van Laarhoven HWM
Int J Cancer; 2019 Nov; 145(10):2792-2803. PubMed ID: 31018252
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
Yoshii T; Ohkawa S; Tamai S; Kameda Y
Dis Esophagus; 2013 Jul; 26(5):496-502. PubMed ID: 22676622
[TBL] [Abstract][Full Text] [Related]
20. Early-stage adenocarcinoma of the esophagus with mid to deep submucosal invasion (pT1b sm2-3): the frequency of lymph-node metastasis depends on macroscopic and histological risk patterns.
Manner H; Wetzka J; May A; Pauthner M; Pech O; Fisseler-Eckhoff A; Stolte M; Vieth M; Lorenz D; Ell C
Dis Esophagus; 2017 Feb; 30(3):1-11. PubMed ID: 26952572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
